Osteoclast differentiation pathway

The "Osteoclast differentiation pathway" refers to a complex network of molecular signals that regulate the formation and maturation of osteoclasts—specialized cells responsible for bone resorption. This process is primarily driven by the receptor activator of nuclear factor kappa-B ligand (RANKL) and involves downstream activation of key signaling cascades such as NF-kB, MAPK/ERK, p38 MAPK, and transcription factors like NFAT. Dysregulation or excessive activation of this pathway leads to increased osteoclastic activity and bone loss seen in diseases such as osteoporosis and metastatic bone disease. While not a single molecule or receptor but rather an entire biological process/pathway involving multiple targets (e.g., SIK3 kinase[1], AKT1, CASP3, MMP9[2]), inhibition of this pathway is considered a therapeutic strategy for conditions characterized by excessive bone resorption. Drugs like regorafenib inhibit several components within this cascade to reduce osteoclast formation and function without significant cytotoxicity at effective doses[2]. Similarly, small molecules such as pterosin B target specific kinases involved in the metabolic regulation required for osteoclastogenesis[1]. However, "Osteoclast differentiation pathway" itself is not a canonical drug target but rather describes a collection of molecular targets within a defined biological process. Note: The entry "Osteoclast differentiation pathway inhibition" does not refer to a single molecule or protein but instead describes modulation/inhibition of an entire cellular process; therefore it should be flagged as incorrect if used where only individual molecular targets are appropriate.

Other names

Osteoclastogenesis pathwayOsteoclast differentiation signalingRANKL-induced osteoclast differentiation pathway

- Inhibition of RANKL-induced NF-kB, ERK, p38 MAPK, and NFAT signaling pathways (by regorafenib)[2] - Inhibition of SIK3-mediated metabolic regulation (by pterosin B)[1]